WoS İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/6

Browse

Filters

2023 - 20252

Settings

COAR Access Rights: search.filters.coarAccessRights.open accessSubject: search.filters.subject.Glioblastoma

Search Results

Now showing 1 - 2 of 2
  • Article
    Citation - WoS: 1
    Safety and Efficacy of Depatuxizumab Mafodotin Monotherapy or in Combination With Temozolomide in Patients With/Without EGFR-Amplified Recurrent Glioblastoma: A Systematic Review
    (Lippincott Williams & Wilkins, 2025) Moghib, Khaled; Hassan, Malak A.; Eljadid, Ghaith Y.; Salomon, Izere; Algazar, Mansour A.; Abu Arafeh, Muhannad Wael; Ibrahim, Ismail A.
    This study aimed to assess the safety and efficacy of depatuxizumab mafodotin as a monotherapy or in combination with temozolomide in patients with recurrent epidermal growth factor receptor (EGFR)-amplified glioblastoma multiforme, focusing on overall survival (OS) and progression-free survival (PFS). A comprehensive literature search was conducted across PubMed, Cochrane Library, Web of Science, and Scopus databases up to August 2024. Randomized controlled trials (RCTs) and observational studies were included, comparing depatuxizumab mafodotin alone or with temozolomide in patients with and without EGFR amplification. Data extraction encompassed participant demographics, treatment regimens, and clinical outcomes. Of 102 screened publications, 10 RCTs and cohort studies involving 1431 patients met the inclusion criteria. The included studies examined depatuxizumab mafodotin as a standalone therapy and in combination with other agents, revealing OS ranging from 5 to 14 months and considerable variability in PFS. While depatuxizumab mafodotin shows the potential to improve survival outcomes, the heterogeneity in results highlights the need for further research. Future studies should refine patient selection criteria and explore alternative therapeutic combinations, such as depatuxizumab mafodotin with gemcitabine or cisplatin, to optimize treatment strategies.
  • Review
    Citation - WoS: 7
    Citation - Scopus: 6
    The Impact of Interaction Between Verteporfin and Yes-Associated Protein 1/Transcriptional Coactivator With Pdz-Binding Motif-Tea Domain Pathway on the Progression of Isocitrate Dehydrogenase Wild-Type Glioblastoma
    (Sage Publications Ltd, 2023) Osama, Mahmoud; Essibayi, Muhammed Amir; Osama, Mona; Ibrahim, Ismail A.; Mostafa, Mostafa Nasr; Eksi, Murat Sakir; Şakir Ekşi, Murat; Nasr Mostafa, Mostafa
    Verteporfin and 5-ALA are used for visualizing malignant tissue components in different body tumors and as photodynamic therapy in treating isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM). Additionally, verteporfin interferes with Yes-associated protein 1 (YAP)/Transcriptional coactivator with PDZ-binding motif - TEA domain (TAZ-TEAD) pathway, thus inhibiting the downstream effect of these oncogenes and reducing the malignant properties of GBM. Animal studies have shown verteporfin to be successful in increasing survival rates, which have led to the conduction of phase 1 and 2 clinical trials to further investigate its efficacy in treating GBM. In this article, we aimed to review the novel mechanism of verteporfin's action, the impact of its interaction with YAP/TAZ-TEAD, its effect on glioblastoma stem cells, and its role in inducing ferroptosis.